Navigation Links
GenVec Reports Fourth Quarter and 2010 Year-End Financial Results
Date:3/10/2011

ue to increased revenue of $7.5 million generated by our hearing loss and balance disorders  program.  We entered into a research collaboration and license agreement with Novartis in January 2010, which accounted for $3.4 million of revenue in 2010, and a development agreement related to the supply of clinical trial material related to activities under the collaboration agreement in August 2010, which accounted for $4.4 million in revenue in 2010.  The two Novartis agreements resulted in increased revenue in 2010 as compared to 2009 when the only work performed for our hearing loss and balance disorders program was performed under a grant from the University of Kansas. Partially offsetting the increased revenue associated with our hearing loss and balance disorders program is decreased revenue of $3.0 million and $2.2 million associated with our HIV and FMD programs, respectively, as compared to the prior years due to reduced work scope under each program.

Operating expenses for 2010 decreased 9% to $29.1 million from $31.9 million in 2009.  Research and development expenses decreased 15% to $20.9 million in 2010 from $24.7 million in 2009. The decrease is primarily due to lower costs related to the development of TNFerade including personnel, manufacturing costs, patient costs, and professional service costs related to our TNFerade pancreatic clinical trial, due to the termination of the clinical trial in the first quarter of 2010.  

General and administrative expenses increased 14% to $8.2 million in 2010 from $7.2 million in 2009. General and administrative expenses were higher in 2010 primarily due to higher professional service costs and facility costs, partially offset by lower depreciation costs.

Fourth Quarter 2010 ResultsFor the fourth quarter ended December 31, 2010, GenVec reported a net loss of $1.0 million, or $0.01 per share, compared with a net loss of $4.3 million, or $0.04 per share, for the comparab
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GenVec Forms Collaboration With World-Leading Animal Health Company
2. GenVec Reports Third Quarter 2010 Financial Results
3. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
4. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
5. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
6. Transgenomic Reports Fourth Quarter Financial Results
7. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
8. Six-Month Prospective Multi-Center Study Reports Efficacy Rates for AMS Elevate Anterior and Apical Prolapse Repair System
9. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
10. Cardiogenesis Reports Fourth Quarter and Full Year 2010 Results
11. Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Reproductive Medicine ... leader in the field of infertility, presents new ... embryonic screening. The research abstract, released during the ... Medicine (ASRM) meeting in Honolulu, Hawaii ... single gene defect (SGD) pre-implantation genetic diagnosis (PGD). ...
(Date:10/22/2014)... -- AVACEN Medical announced today that its AVACEN 100 ... by the U.S. Food and Drug Administration. This clearance ... Internet for: the temporary relief of joint pain ... sprains . Logo - http://photos.prnewswire.com/prnh/20141021/153513 ... a sophisticated medical device incorporating over 3,000 firmware instructions ...
(Date:10/22/2014)... 2014  With a vision to ensure safety ... Global Pharmaceutical and Biotech manufacturer selects and implements ... solution to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... aggregated by the Xyntek and Antares solution is ...
Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... A Commonwealth Fund case study notes that ... aligned "to launch innovations and organize services in ways that make ... study -- along other profiles looking at medical systems that have ... high performing health care system -- has been in the works ...
... Conatus Pharmaceuticals Inc. announced today the initiation of a ... for the treatment of liver disease associated with Hepatitis C ... treatment with approved standard of care treatments is not currently ... patients who failed standard of care treatment are expected to ...
Cached Medicine Technology:Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative 2Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative 3Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis 2
(Date:10/22/2014)... October 22, 2014 Akeso Biomedical, ... for the treatment of bacterial infections, microbial biofilms, and ... joined its board of directors. , Dr. ... Systems at The Massachusetts Institute of Technology, or MIT. ... since 1968. Dr. Sinskey also holds positions as Co-Director ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... are only about half as likely as white women to ... indicates, and the racial disparity persists even when donor eggs ... white patients became pregnant after IVF, compared to about 17 ... cycles over two years to tease out the impact of ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... to increased blood pressure, according to a new study. ... pressure for young adult women or for teenagers, according to ... or moderately, their risk of high blood pressure was cut ... in older adult men and women," said lead researcher Dr. ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
(Date:10/22/2014)... Thompson HealthDay Reporter TUESDAY, Oct. ... with Ebola while working for NBC News in Liberia ... special isolation unit at Nebraska Medical Center in Omaha, where he ... Tuesday. A blood test confirmed by the U.S. Centers for ... home to Providence, R.I., NBC News reported Tuesday night. ...
Breaking Medicine News(10 mins):Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... ... were also desperate pioneers whose drug use had gotten the better of them ... test whether an epilepsy drug could reduce their use of cocaine. In the ... spent the final three weeks of the study with no signs of cocaine ...
... Urges U.S. Senate to Support and Pass Landmark Health Care ... U.S. House of Representatives, historic vote on health care reform ... system - but for millions of Americans struggling with soaring ... and pass the Affordable Health Care for America Act (H.R. ...
... , WASHINGTON, Nov. 11 An article running in ... American Medical Association , "Silent Epidemic of Viral Hepatitis ... the urgent need for Congress to act on new ... a comprehensive prevention, research, and medical management referral program ...
... ROCHESTER, N.Y., Nov. 11 The University of Rochester ... center that will assist researchers studying the electrical activity ... safety, understanding cardiac arrhythmias, and developing new electrocardiograph technologies. ... -- funded by a $2.3 million grant from the ...
... Association,s House of Delegates elected Paula Anderson, RNC to the ... Anderson succeeds Barbara A. Nash MS, RN, C, CNS, who ... ONA. , Anderson is a Staff Nurse at The ... been a bedside Registered Nurse for almost 40 years. She ...
... This holiday season, Ingenious Med is partnering with Children,s Restoration ... 2,000 Metro-Atlanta children living in group homes and shelters. ... an effort to stock 129 shelters with basic needs as ... Ingenious Med to host these food drives throughout Atlanta. ...
Cached Medicine News:Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 2Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 3Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 4Health News:House Health Reform Plan Will Benefit Millions of Illinoisans 2Health News:NVHR: New JAMA Article Underscores Urgent Need for Congress to Act on Viral Hepatitis Detection, Management Funding 2Health News:New Research Center to Focus on Cardiac Safety and Innovation 2Health News:New Research Center to Focus on Cardiac Safety and Innovation 3Health News:Ohio Nurses Association Announces New President; 2009-2011 Board of Directors 2Health News:Ingenious Med Partners with Children's Restoration Network for Holiday Charity 2
... Propel Cannulated Interference Screw ... unbiased, symmetrical starts, while limiting ... distal end reduces abrasion where ... unequalled protection. Aggressive-pitch thread enables ...
Cannulated Interference Screws...
Cannulated Interference Screws...
... CoEase is designed to provide excellent protection ... unique advantage of being closer to an ... This allows CoEase to maintain viscosity ... best of both worlds for superb performance ...
Medicine Products: